Merck maintains a 'strong buy' rating due to its proactive expansion in oncology to offset the KEYTRUDA patent expiration in 2028. The acquisition of Terns Pharmaceuticals adds TERN-701, a promising oral drug for chronic myeloid leukemia with multibillion-dollar potential and FDA Breakthrough Therapy status. Merck is also advancing the KEYTRUDA family with new formulations and combination therapies, aiming for approvals in bladder and renal cancers by 2026. Strong Q1 2026 revenues of $16.3 billion, including $8 billion from KEYTRUDA and significant growth in WINREVAIR, support confidence in Merck's pipeline execution.

More News (MRK)

Healthcare ETFs offer defensive stability and growth through biotech, pharma, and weight-loss innovations.

Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...

Market News

Bullish

4 days ago

Merck keeps 'strong buy' rating with oncology pipeline growth and new drug approvals through 2026.

More News (MRK)

Healthcare ETFs offer defensive stability and growth through biotech, pharma, and weight-loss innovations.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Merck keeps 'strong buy' rating with oncology pipeline growth and new drug approvals through 2026.

More News (MRK)

Healthcare ETFs offer defensive stability and growth through biotech, pharma, and weight-loss innovations.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App